Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

NCT06482086 ↗

Phase 2 Recruiting 75 enrolled West China Hospital

NaSingle-groupOpen-labelTreatment

Summary

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Timeline

Start: 2021-06-01
Primary completion: 2024-12-01
Completion: 2025-12-01

Publications

Guo Z, Liu J, Zhang X, Ma Y, Wang Y, Li P, Huang R, Li Z; MDT of Advanced Thyroid Cancer of West China Hospital. Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study. Endocrine. 2025 Jul;89(1):186-196. doi: 10.1007/s12020-025-04240-9. Epub 2025 Apr 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabozantinib	Small molecule	60 mg	Oral
Subject	Catequentinib	Small molecule	8 mg	Oral
Subject	Catequentinib	Small molecule	10 mg	Oral
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Dabrafenib	Small molecule	150 mg	Oral
Subject	Donafenib	Small molecule	0.3 g	Oral
Subject	Entrectinib	Small molecule	600 mg	Oral
Subject	Everolimus	Small molecule	10 mg	Oral
Subject	Larotrectinib	Small molecule	100 mg	Oral
Subject	Lenvatinib	Small molecule	8 mg	Oral
Subject	Lenvatinib	Small molecule	12 mg	Oral
Subject	Pralsetinib	Small molecule	400 mg	Oral
Subject	Rivoceranib	Small molecule	500 mg	Oral
Subject	Sorafenib	Small molecule	0.4 g	Oral
Subject	Trametinib	Small molecule	2 mg	Oral
Subject	Vandetanib	Small molecule	300 mg	Oral

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Summary

Timeline

Publications

Drugs

Indications